Argosulfan, 2% cream 40 g
€18.08 €15.67
Preparation with antibacterial action for external use. It promotes healing of wounds (burns, trophic, purulent), provides effective protection from infection, reduces treatment time and wound preparation time for skin grafting, in many cases leads to improvement of condition excluding the need for transplantation.
The silver sulfonamide contained in the cream is an antimicrobial and bacteriostatic agent that has a broad spectrum of antibacterial action against Gram-positive and Gram-negative bacteria.
The mechanism of antimicrobial action of sulfathiazole – inhibition of microbial growth and reproduction – is associated with competitive antagonism with para-aminobenzoic acid and inhibition of dihydropteroate synthetase, which leads to disruption of dihydrofolic acid synthesis and eventually its active metabolite – tetrahydrofolic acid, required for synthesis of purines and pyrimidines of microbial cells.
Silver ions present in the drug enhance antibacterial action of sulfonamide – they inhibit bacterial growth and division by binding to deoxyribonucleic acid of the microbial cell. In addition, silver ions weaken the sensitizing properties of sulfonamidanilamide. Due to minimal resorption, the drug has no toxic effect.
Indications
burns of varying degrees of any etiology (including thermal, solar, chemical, electric shock, radiation);
frostbite;
bedsores;
trophic ulcers of the leg of various origins (including chronic venous insufficiency, obliterating endarteritis, circulatory disorders due to diabetes mellitus, erysipelas);
purulent wounds;
minor household injuries (cuts, abrasions);
infected dermatitis, impetigo, simple contact dermatitis, microbial eczema, streptostaphyloderma.
Pharmacological effect
Argosulfan® is a topical antibacterial drug that promotes wound healing (burn, trophic, purulent), provides effective protection of wounds from infection, reduces treatment time and time to prepare a wound for skin grafting, in many cases leading to an improvement in condition, eliminating the need for transplantation.
The sulfanilamide contained in the cream – silver sulfathiazole – is an antimicrobial bacteriostatic agent and has a wide spectrum of antibacterial action against gram-positive and gram-negative bacteria. The mechanism of the antimicrobial action of sulfathiazole – inhibition of the growth and reproduction of microbes – is associated with competitive antagonism with para-aminobenzoic acid and inhibition of dihydropteroate synthetase, which leads to disruption of the synthesis of dihydrofolic acid and, ultimately, its active metabolite – tetrahydrofolic acid, necessary for the synthesis of purines and pyrimidines of the microbial cell. The silver ions present in the drug enhance the antibacterial effect of sulfonamide – they inhibit the growth and division of bacteria by binding to the deoxyribonucleic acid of the microbial cell. In addition, silver ions weaken the sensitizing properties of sulfonamide.
Due to minimal resorption, the drug has no toxic effect.
Special instructions
If you are taking metoclopramide, domperidone or cholestyramine, you should also consult your doctor.
With long-term use in doses significantly higher than recommended, the likelihood of impaired liver and kidney function increases; monitoring of the peripheral blood picture is necessary.
Paracetamol and ascorbic acid can distort laboratory tests (quantitative determination of glucose and uric acid in blood plasma, bilirubin, liver transaminase activity, LDH).
To avoid toxic liver damage, paracetamol should not be combined with alcoholic beverages, or taken by persons prone to chronic alcohol consumption. The risk of developing liver damage increases in patients with alcoholic hepatosis.
Prescribing ascorbic acid to patients with rapidly proliferating and intensively metastasizing tumors can aggravate the process.
In patients with high iron levels in the body, ascorbic acid should be used in minimal doses.
Active ingredient
Silver sulfathiazole
Composition
1 g
silver sulfathiazole 20 mg
Excipients: cetostearyl alcohol, liquid paraffin, white petrolatum, glycerol, sodium lauryl sulfate, methyl parahydroxybenzoate, propyl parahydroxybenzoate, potassium dihydrogen phosphate, disodium phosphate dodecahydrate, water for injection.
Pregnancy
The use of Argosulfan® during pregnancy and lactation is possible only in cases where the burn surface does not exceed 20% of the body surface, and when, according to the doctor’s assessment, the potential benefit to the mother is greater than the possible risk to the fetus and child.
Contraindications
Hypersensitivity (including to other sulfonamides).
Congenital deficiency of glucose-6-phosphate dehydrogenase.
Early childhood (newborns and infants up to 2 months, premature babies) due to the risk of developing kernicterus.
Not recommended for use during pregnancy.
During breastfeeding, the drug can be prescribed only if the burn surface does not exceed 20% of the body surface, and the therapeutic benefit to the mother is greater than the possible risk to the child.
Side Effects
Possible: allergic reactions, local reactions (burning, itching, skin flushing).
With prolonged use, leukopenia and desquamatous dermatitis are possible.
Interaction
It is not recommended to use together with other local medications.
Folic acid and its structural analogues (for example, procaine) can weaken the antimicrobial effect of sulfathiazole.
Overdose
No cases of overdose have been reported.
Storage conditions
The drug should be stored out of the reach of children at a temperature not exceeding 25°C. Do not freeze
Shelf life
Shelf life – 2 years. Do not use after expiration date.
After opening the tube, store for no more than 6 months.
Manufacturer
Pharmaceutical plant Elfa A.O., Poland
Shelf life | 2 years. |
---|---|
Conditions of storage | At a temperature of 5°C to 15°C. |
Manufacturer | Jelfa Pharmzavod, Poland |
Medication form | exterior cream |
Brand | Jelfa Pharmzavod |
Other forms…
Related products
Buy Argosulfan, 2% cream 40 g with delivery to USA, UK, Europe and over 120 other countries.